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Abstract 32	
The manufacture of immediate release high drug loading paracetamol oral tablets was 33	
achieved using an extrusion based 3D printer from a premixed water based paste formulation. 34	
The 3D printed tablets demonstrate that a very high drug (paracetamol) loading formulation 35	
(80% w/w) can be printed as an acceptable tablet using a method suitable for personalisation 36	
and distributed manufacture. Paracetamol is an example of a drug whose physical form can 37	
present challenges to traditional powder compression tableting. Printing avoids these issues 38	
and facilitates the relatively high drug loading.  39	
The 3D printed tablets were evaluated for physical and mechanical properties including 40	
weight variation, friability, breaking force, disintegration time, and dimensions and were 41	
within acceptable range as defined by the international standards stated in the United States 42	
Pharmacopoeia (USP). X-Ray Powder Diffraction (XRPD) was used to identify the physical 43	
form of the active. Additionally, XRPD, Attenuated Total Reflectance Fourier Transform 44	
Infrared spectroscopy (ATR-FTIR) and differential scanning calorimetry (DSC) were used to 45	
assess possible drug-excipient interactions. The 3D printed tablets were evaluated for drug 46	
release using a USP dissolution testing type I apparatus. The tablets showed a profile 47	
characteristic of the immediate release profile as intended based upon the active/excipient 48	
ratio used with disintegration in less than 60 seconds and release of most of the drug within 5 49	
minutes. The results demonstrate the capability of 3D extrusion based printing to produce 50	
acceptable high-drug loading tablets from approved materials that comply with current USP 51	
standards. 52	
 53	
 54	
 55	
 56	
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1.1. Introduction 57	
Paracetamol is available in many different dosage forms including tablets, capsules, 58	
suspensions, suppositories and intravenous solutions and is commonly used to alleviate mild 59	
to moderate pain caused by headaches, toothache, sprain, or strains (Whittaker, 2011). It is 60	
usually used in oral solid dosage forms in an active dose range from 300-500 mg, although 61	
1000 mg is also available in some regions. Direct compression is the most common method 62	
used for tableting production (Gohel and Jogani, 2005), as it is a relatively straightforward 63	
process compared with other tablet manufacturing process such as wet granulation. However, 64	
direct compression is limited to relatively low drug loading tablet production due to the 65	
mechanical properties of some actives, including paracetamol, compromising compression 66	
characteristics. Poorly compressible active ingredients mean that only 30-40 % w/w of the 67	
active can be accommodated and therefore, production of 500 mg paracetamol tablets 68	
requires compression of a formulation with a final weight of 1300 mg including 800 mg of 69	
excipients. This can cause patient non-compliance due to the large tablets being difficult to 70	
swallow or even to choking (Gohel and Jogani, 2005, Govedarica et al., 2009, Kaerger et al., 71	
2004). Segregation of powder constituents and dust contamination are another problems in 72	
the direct compression process (Gohel and Jogani, 2005). This can be addressed by 73	
granulation, a process well known in the manufacturing of paracetamol tablets. This process, 74	
however, also has some limitations compared with extrusion based 3D printing process. 75	
These include; lower paracetamol loading leading to a higher final product total weight, 76	
material loss during the various stages of processing and multiple processing steps adding 77	
complexity (Agrawal and Naveen, 2011). This could in general make 3D printing an 78	
attractive way of manufacturing tablets using inexpensive single step. 79	
Paracetamol exists in three different polymorphs; forms I, II, and III; exhibiting different free 80	
energies and different physicochemical properties such as melting point, stability, dissolution 81	
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rate, deformation characteristics (affecting compressibility) and crystal shape and size 82	
(affecting powder density and flow properties) (Capes and Cameron, 2007, Di Martino et al., 83	
1997, Sibik et al., 2014). Paracetamol form I is preferred in tablet production because it is the 84	
most stable form (Nichols and Frampton, 1998). However, the crystals of paracetamol form I 85	
display low flowability and a poor compression ability, and when such crystals compressed 86	
into tablets they show massive elastic deformation under pressure and a tendency to cause 87	
problems with tablets such as chipping, capping, stress cracking, lamination, sticking and 88	
picking (Eichie and Amalime, 2007, Govedarica et al., 2009, Karki et al., 2009, Martinello et 89	
al., 2006, Ngwuluka et al., 2010, Wu et al., 2008). In order to reduce the above-mentioned 90	
problems and improve compressibility, paracetamol tablets are typcially prepared by adding a 91	
high quantity of excipients such as starch, carboxymethyl cellulose, pre-gelatinized starch, 92	
and gelatine (direct compression) or by the addition of binders (granulation process) 93	
(Martinello et al., 2006, Ngwuluka et al., 2010). Each one of these additions can introduce 94	
expense and increasing tablet weight and size (Di Martino et al., 1996, Fachaux et al., 1995, 95	
Khaled et al., 2014). There is little work on 3D printing of paracetamol formulations in the 96	
literature and these are mostly by FDM 3D printing (Goyanes et al., 2017, Goyanes et al., 97	
2016, Wang et al., 2016). However, the high extrusion temperatures applied (≥180 °C) using 98	
FDM narrow the active ingredient library that can be used by this process to include only heat 99	
stable actives. Also, the print resolution is affected by the drug loading leading to partial loss 100	
in the object morphology definition at high loading, and therefore affecting the final product 101	
quality (Goyanes et al., 2017)  102	
3D printed oral tablets manufactured via different 3D printers have been demonstrated (Clark 103	
et al., 2017, Goyanes et al., 2015, Holländer et al., 2016, Kyobula et al., 2017, Rattanakit et 104	
al., 2012, Rowe et al., 2000, Skowyra et al., 2015, Sun and Soh, 2015, Wang et al., 2016). 105	
Spritam® was the first FDA approved 3D printed medicine manufactured by the 106	
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pharmaceutical company, Aprecia, in which the active is the anti-epileptic drug 107	
levetiracetam. The tablets were printed with high drug loading using a continuous process of 108	
spreading a layer of powder onto a movable piston plate, during which the drug/additives 109	
particles were bound together to form a solid layer by the spreading of a liquid binder 110	
solution. The printing process was repeated continuously until the desired tablet dimension is 111	
achieved. This method of printing was also demonstrated by Katstra et al. who showed that 112	
problems related to ink bleeding, drug migration, and the capillary effect of the binder on the 113	
powder bed (formulation/binder saturation), geometry restrictions and organic solvent 114	
residues mean that it is suitable only for a small range of excipients and drugs (Katstra et al., 115	
2000, Rowe et al., 2000, Wang et al., 2016). Drug loading limits and the consequences of 116	
printing at high temperature are known issues in other 3D printing methods of tablet 117	
production (Gohel and Jogani, 2005, Goyanes et al., 2015) due to ink (printable formulation) 118	
rheology and drug degradation in the 3D printing technologies available. This is particularly 119	
so for inkjet and fused deposition modelling (FDM) methods, respectively. However, the 120	
drug loading of FDM has been reported to be able to reach 50% (Pietrzak et al., 2015). 121	
We propose that a paste-based extrusion 3D printing process using standard pharmaceutical 122	
excipients will be applicable to a wider range of drugs and excipients and allows higher drug 123	
loading (Khaled et al., 2014, Khaled et al., 2015, Khaled et al., 2015). Additional advantages 124	
include the avoidance of possible drug degradation caused by the high temperatures and UV 125	
irradiation used in FDM and UV-curing based ink-jet methods, respectively (Okwuosa et al., 126	
2016). Furthermore, extrusion is generally a well understood process being used in 127	
pharmaceutical and other industries for many years and the materials used in extrusion 128	
process already having compendia grades available for pharmaceutical applications. 129	
However, extrusion based 3D printing does have a number of disadvantages; relatively coarse 130	
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resolution compared with inkjet, SLS, and SLA 3D printers, not suitable for humid sensitive 131	
materials (degradation) and a risk of phase separation. 132	
1.2. Material and methods 133	
1.2.1.  Materials 134	
Paracetamol, polyvinylpyrrolidine (PVP K25), sodium phosphate monobasic and dibasic 135	
were supplied by Sigma–Aldrich (Gillingham, UK). Croscarmellose sodium (CCS) 136	
(Primellose®) was kindly supplied as a gift from DFE Pharma. Milli-Q water (resistivity 18.2 137	
MΩ cm) was used for all formulations and solutions.  138	
1.2.2. Methods 139	
1.2.2.1.  Design of paracetamol tablets 140	
An oval shaped tablet was chosen as a style of tablet made to be easy to swallow. The 3D 141	
tablet was designed to achieve an immediate drug release profile based upon the 142	
active/excipient ratio used. The dimension of the designed oval tablet was 14.5 mm length × 143	
7.5 mm width × 4.9 mm height. The number of the printed layers was 14 with a 0.35 mm 144	
thickness for each layer. The selected tablet size and shape could improve patient compliance 145	
with medication regimen (Brotherman et al., 2004, Channer and Virjee, 1986, Hey et al., 146	
1982). The geometry of the 3D printed tablets was programmed using a 3D drawing package 147	
(BioCAD, regenHU Villaz-St-Pierre, Switzerland). 148	
1.2.2.2. Extrusion based 3D printing process of paracetamol tablets 149	
Paracetamol powder was ground using a standard coffee machine to achieve particles less 150	
than 100 um diameter (mesh with pores of 100 um diameter was used to sieve ground 151	
paracetamol powder). The paracetamol ground powder and the required excipients (CCS and 152	
PVP K25) were mixed using a mortar and pestle for 15 min. Two grams of the blend were 153	
accurately weighed and mixed to form a paste with 1.3 ml of Milli-Q water (the disintegrant 154	
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(NaCCS) was responsible for the addition of a high amount of water) according to the 155	
formulae shown in Table 1. 156	
1.2.2.3.Cartridge tool filling and 3D printing processes   157	
A plastic 5 cm3 syringe (Optimum® syringe barrels, Nordson EFD) was used to fill the paste 158	
into the syringe cartridge in the 3D printer (regenHU 3D printer). A stopper was fixed into 159	
Luer-Lock thread at the top end of the barrel after the filling process to avoid any 160	
unintentional leakage of paste from the cartridge. Once ready for printing, the stopper was 161	
removed, and the required nozzle (Optimum® SmoothFlow™ tapered dispensing tips, 31.24 162	
mm length, Nordson EFD) was installed. The inserted piston was pushed upwards to remove 163	
any trapped air in the barrels and to deliver the paste into the nozzle. The filled cartridge was 164	
then installed into the printer head and the paste was extruded layer by layer until the desired 165	
tablet dimension was reached.	The printed tablets were left on a heated printing platform (80 166	
°C) for 3 hours for complete drying (Figure 1) and (supplementary data, Appendix A, Figure 167	
S.I. 1 and Table S.I. 1). The following printing parameters were used; extrusion temperature 168	
was 23 °C, speed while travelling (6 mm/s) and layer height (0.40mm). The infill percentage 169	
was 100% to avoid void formation inside the tablets and to produce tablets with high density. 170	
Tip diameter 0.4 mm, printing pressure = 1.8 bar, number of printed layers = 14, and total 171	
printing time = 8 min/tablet.  172	
1.2.2.4. Dissolution studies 173	
In vitro drug release studies of the paracetamol immediate release 3D printed tablets were 174	
performed using a USP Type I apparatus (rotation speed at 30 rpm, 900 ml phosphate buffer, 175	
pH 6.8 as the dissolution media at 37±0.5 °C). 5.0 ml samples were withdrawn at 5, 10, 15, 176	
20, and 30 min. The samples were centrifuged and 0.5 ml from the supernatant was drawn 177	
and diluted to 10 ml using the dissolution medium. The samples were analysed with UV–vis 178	
spectrophotometer (Cary® 50 UV-vis spectrophotometer) at a λ max of 243 nm. Drug 179	
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dissolution studies were conducted in sextuplicate and the average of percentage of 180	
cumulative drug release as a function of time was determined. The calibration curve was 181	
prepared using the same dissolution medium (a phosphate buffer medium at pH 6.8) and used 182	
to identify concentration of paracetamol in the unknown samples (Supplementary data, 183	
Appendix A, Figure S.I. 2). 184	
1.2.3. Characterization techniques  185	
1.2.3.1. XRPD 186	
The XRPD patterns of pure paracetamol and paracetamol immediate release formulation 187	
powder (powder mixture after tablet ground into powder) were obtained at room temperature 188	
using an X'Pert PRO (PANalytical, Almelo, Netherlands) setup in reflection mode using Cu 189	
Kα1 (lambda =1.54 Å) operating in Bragg–	Brentano geometry. The generator voltage was set 190	
to 40 kV and the current to 40 mA and the samples were scanned over 2θ range of 5° until 30° 191	
in a step size of 0.026°. 192	
1.2.3.2. ATR-FTIR 193	
Infrared spectra of pure paracetamol powder and the selected excipients (CCS and PVP K25) 194	
were obtained using an ATR-FTIR (Agilent Cary 630 FTIR) spectrometer. 195	
1.2.3.3. DSC 196	
DSC was used to determine and compare paracetamol melting point in its pure and mixture 197	
state, and to determine possible interactions between the constituents. The DSC 198	
measurements were performed on TA Instruments' DSC Q2000 coupled to Universal 199	
Analysis 2000 with a thermal analyzer. DSC analysis on such drug-excipient mixtures was 200	
obtained by grinding paracetamol tablets and sieving the powders (<150 µm). Accurately 201	
weighed samples of 3-5 mg of the powder were placed and sealed in aluminium pans. The 202	
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scan was performed under nitrogen flow (50 mL/min) at a heating rate of 10° C/min from 35° 203	
C to 200° C. An empty sealed aluminium pan was used as reference. 204	
1.2.3.4. Scanning electron microscopy (SEM)  205	
Variable pressure scanning electron microscopy (JEOL 6060LV, UK) was used to 206	
characterize the surface morphology of the paracetamol immediate release tablets at three 207	
different positions (top, cross section and bottom). The SEM images were taken at different 208	
magnifications for the samples. The samples were mounted onto carbon tape stubs and 209	
sputter coated with gold (Leica EM SCD005 Sputter Coater). 210	
1.2.4. Physical properties of the paracetamol immediate release 3D printed tablets 211	
1.3.4.1. Weight test 212	
Twenty paracetamol immediate release 3D printed tablets were individually weighed and 213	
their average weight calculated. The individual tablet weight deviation (%) was calculated. 214	
1.3.4.2. Breaking force 215	
Tablet breaking force is a USP test used to measure crushing strength and structural integrity 216	
of tablets. Six paracetamol 3D printed tablets were randomly selected and tested for breaking 217	
force using a hardness tester (Hardness tester C50, I Holland Ltd., Holland). The breaking 218	
force values were recorded in N (Newton) units and the average values were calculated (Pitt 219	
and Heasley, 2013). 220	
1.3.4.3. Friability 221	
Twenty paracetamol 3D printed tablets were selected randomly and the tablets were 222	
accurately weighed (initial weight). The tablets were placed in a friability tester and rotated at 223	
a constant speed of 25 rpm for a period of 4 min in Erweka friabilator. The tablets were 224	
cleaned from loose dust and reweighed (final weight) and the weight loss % (friability) 225	
calculated. 226	
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1.3.4.4. Dimension of paracetamol immediate release 3D printed tablets 227	
The tablet dimension values were recorded using Vernier callipers and their average values 228	
calculated. 229	
1.3.4.5. Disintegration test of the paracetamol immediate release 3D printed tablets 230	
A disintegration test was carried out on six paracetamol immediate release 3D printed tablets 231	
using a disintegration tester (Copley Scientific, UK). Six tablets were placed in a basket-rack 232	
composed of six tubes raised and lowered at a frequency rate between 29 and 32 cycles per 233	
minute, with 1000 ml deionised water as the dissolution media at 37 ±0.5 °C. The 234	
disintegration test was considered successful if all tablets were disintegrated and passed 235	
through a 10-mesh screen at the bottom end of the basket-rack. 236	
1.3. Results and discussion 237	
1.3.1.  Tablet printing 238	
Batches of tablets were printed following the outlined method. Examples are shown in Figure 239	
1. 240	
1.3.2. Tablet morphology 241	
Figure 2 shows examples of the paracetamol oval tablets. There are some small lines visible 242	
on the top of the tablets due to the paracetamol paste strands when printing. These lines can 243	
be reduced if a tip with smaller internal diameter is used, although this increases print time. 244	
Oval tablets were printed as studies have concluded that round tablets are more difficult to 245	
swallow and have a slower esophageal transit times than oval tablets of the same weight 246	
(Hey, Jørgensen et al. 1982, Channer and Virjee 1986). Figure 3 shows examples of the 247	
microstructure of paracetamol tablets (top, cross section, and bottom). 248	
 249	
 250	
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1.3.3. In vitro drug dissolution 251	
Dissolution data from the paracetamol 3D printed tablets show that more than 90% of the 252	
paracetamol was released within the first 10 min (Figure 2). This rapid drug release is 253	
attributed to the inclusion of the disintegrant sodium crosscarmellose, which rapidly absorbs 254	
water and swells leading to the disintegration of the tablets. Furthermore, the formation of a 255	
microporous structure (Figure 3) due to the evaporation of water from the 3D printed tablets 256	
during drying also facilitated the dissolution medium penetration, fast disintegration and 257	
rapid drug release. 258	
1.3.4. XRPD 259	
XRPD of the pure as-received paracetamol powder before printing, and the tablets was done 260	
to investigate any changes in physical form on printing (Figures 4 and 5). The Bragg peaks 261	
observed from the pure paracetamol (as received) match the Bragg peaks of paracetamol 262	
(calculated) reported in the Cambridge Structural Database (CSD) (Figure 4). 263	
The results in figure 5 shows that the paracetamol (non-ground and ground powder) exhibited 264	
multiple sharp Bragg peaks in their XRPD patterns related to their crystalline nature. The 265	
post-printing XRPD data show that the same Bragg peaks for the paracetamol were still 266	
present. There was, therefore no evidence of a change in physical form (Form I) for the 267	
paracetamol in this formulation fabricated using extrusion based 3D printing. As we used a 268	
significant quantity of water and PVP K25 as a binder, we believe that a portion of the 269	
paracetamol powder could have dissolved in the water (paracetamol solubility 12.78 g/l /20 270	
°C) (Granberg and Rasmuson, 1999) as the whole mixture formed a paste, however this must 271	
have recrystallised back into form I if this had occurred. XRPD also did not show evidence of 272	
incompatibility between paracetamol and the chosen excipients ((PVP K25 (11.25 %) and 273	
CCS (8.75 %)) in the tablets (Figure 5). 274	
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1.3.5.  ATR-FTIR 275	
Infrared spectral data show the characteristic peaks positions remained unchanged from the 276	
paracetamol powder to the formulation, indicating that there were no detectable interactions 277	
between the paracetamol and the selected excipients (PVP K25 (11.25 %) and CCS (8.75 %)) 278	
(Figure 6). 279	
1.3.6.  DSC 280	
DSC analysis was performed to explore the stability of drug crystallinity after the 3D printing 281	
process (grinding, mixing, paste formulation and drying process on a hot plat heated at 80 282	
°C). DSC data shows that the pure drug powder melts at 169.7 °C confirming the presence of 283	
form I (Sibik et al., 2014) while pure PVP K25 shows a glass transition around 155 °C 284	
(Figure 7). The DSC data of the paracetamol formulation shows clear evidence of an 285	
endothermal event (melting point) at 169.7 °C, indicating that the drug is still in a crystalline 286	
form, specifically form I. This finding was also confirmed by X-ray powder diffraction data 287	
(Figure 5). A further confirmation found from the SEM images of the cross sections view of 288	
paracetamol sold tablets shows the presence of crystals on the surface and the SEM images 289	
corroborates this extent (Fig. 3).  From the above results and discussions we found that DSC 290	
thermogram of paracetamol formulation powder after blending, printing, and post-printing 291	
processes with the excipients; PVP K25 and NaCCS did not show significant changes in peak 292	
placement apart from the peak depression and reduction caused by the presence of the 293	
polymer in the formulation in comparison to the peak obtained from the pure paracetamol 294	
powder and again suggesting compatibility of the excipients.  295	
1.3.7. Physical properties  296	
The 3D printed tablets were evaluated for breaking force, friability, weight variation, tablet 297	
dimension, and disintegration time.  298	
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1.3.7.1. Weight uniformity   299	
In quality control, oral tablets/capsules (dose and ratio of drug substance ≥25 mg and ≥25 %, 300	
respectively) are required to meet the weight variation test and confirm that all 301	
tablets/capsules in a batch are within the acceptable limits (Allen et al., 2011, Jatto and 302	
Okhamafe, 2002). In our case the active (paracetamol) content represents the major part of 303	
the tablets (80 % w/w) and therefore control of the 3D printed tablet total weight is a 304	
satisfactory control for content uniformity of the drug. The paracetamol immediate release 305	
3D printed tablets showed a percentage weight variation within the range of -2.17 to +1.70 306	
and, therefore, comply with the USP specification for uncoated tablets (±7.5%) table 2 (Allen 307	
et al., 2011, Jatto and Okhamafe, 2002). 308	
1.3.7.2. Breaking force 309	
Acceptable tablets should have sufficient strength to resist breaking and mechanical shocks 310	
during transportation and storage. However, tablets also should be soft enough to disintegrate 311	
properly after swallowing and releasing the drug. In a conventional tableting press, the 312	
tablet's breaking force is controlled by compression forces. A tablet with a breaking force of 313	
4 kg or above is considered to be satisfactory (Remington et al., 2006). In contrast, in 3D 314	
printing process, the binder is essentially used to control tablet breaking force rather than 315	
compression force. Examples of binders used in extrusion-based 3D printing process are 316	
PVP, hydroxyl propyl methyl cellulose (HPMC), and hydro-alcoholic gels (Khaled et al., 317	
2014, Khaled et al., 2015). From the data set presented in table 3, breaking force 318	
measurements were within the accepted range of 7.5-8.5 kg, and therefore, comply with USP 319	
specifications. Tensile fracture strength of flat faced oval paracetamol tablets were calculated 320	
using equation 1 (Stanley and Newton, 1980). 321	
σf = 3FL/2bd2                                                                                                                    Eq. 1 322	
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Where (σf) is the tensile fracture strength of the tablet, (F) is the breaking force, (l) is the 323	
tablet length, (b) is the tablet width and (d) is the tablet thickness. 324	
1.3.7.3. Friability 325	
This is a USP test used to determine a tablets resistance to chipping, capping, and abrasion 326	
occurred during manufacturing, packaging, and shipping processes. The paracetamol 327	
immediate release 3D printed tablets showed a percentage of weight loss of 0.54 % which is 328	
within the range of not more than 1% of tablet weight and, therefore, the tablets again meet 329	
USP specifications (Nilawar et al., 2013).  330	
1.3.7.4. Tablet size and dimension  331	
The data in Table 6 confirm that the tablet’s size and dimension printed by extrusion based 332	
3D printing process were reproducible and comparable with the designed tablet’s size and 333	
dimension and with the tablet sizes reported in the literature prepared by conventional 334	
tableting machines (Brotherman et al., 2004, Channer and Virjee, 1986, Hey et al., 1982). 335	
1.3.7.5. Disintegration test 336	
Disintegration testing of oral solid dosage forms is another important physical parameter and 337	
can be a key factor for a good drug bioavailability. Tablets with a fast disintegration time will 338	
have a quicker dissolution time, potentially resulting in improved bioavailability. Table 5 339	
shows that all the 3D printed tablets tested have a disintegration time between 57 s and 66 s 340	
with an average of 61 s and that is therefore within the acceptable range of USP where 30 341	
min is the maximum disintegration time for the majority of the compressed tablets 342	
(Tarannum et al., 2013). 343	
1.4. Potential practice of extrusion based 3D printing process  344	
Customizing medicines for individual patients using a 3D printer is a promising application 345	
that could provide new opportunities for the pharmaceutical industry and for patients. 3D 346	
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printers could potentially be used to print highly tailored medicines, for example with 347	
deposition of different active ingredients separated with a compatible polymer could increase 348	
patient compliance and reduce drug side effects and toxicity. Formulation of multi-prescribed 349	
medicines into one tablet with a tailored dose and desired drug release profile can be a 350	
challenging using a conventional tableting process. Hence, physicians are restricted in 351	
achieving an accurate dosing regimen for a specific patient group according to patient’s 352	
genetic factors, body mass index (BMI) and age (Sandler et al., 2011, Voura et al., 2011). 353	
Furthermore, using 3D printers could eliminate a number of steps in tablet pipeline 354	
production process, such as powder milling, wet granulation, dry granulation, tablet 355	
compression, coating, and long-term stability studying tests especially, when there is limited 356	
quantity of active ingredients at early drug development stage (Voura et al., 2011). 357	
3D printer could also play an important role in bringing the final product closer to the patient 358	
through so-called distributed manufacturing. Distribution manufacturing is defined as raw 359	
materials and methods of fabrications being decentralised and the final product being 360	
manufactured very close to the customer (much like a compounding pharmacists would do 361	
manually). This could offer a quick point of care manufacturing process and fast medicines 362	
supply, producing accurate tailored dose for individuals. The schematic diagram in figure 8 363	
indicates how 3D printing could provide a new method for the drug manufacturing process.  364	
 365	
 366	
 367	
 368	
 369	
 370	
 371	
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1.5. Conclusions 372	
Extrusion based 3D printing of paracetamol immediate release tablets with a very high drug 373	
loading (80 % w/w) was successfully demonstrated. The 3D printed tablets released more 374	
than 90 % of the active within 10 min. XRPD, FTIR, DSC and SEM data show that the 375	
paracetamol form was unaffected by the printing and that there was no detectable interactions 376	
between the paracetamol and the chosen excipients (PVP K25 and CCS). The 3D printed 377	
paracetamol tablets were also evaluated for weight variation, hardness, friability, 378	
disintegration time, and size and dimension and were within acceptable range as defined by 379	
the international standards stated in the USP. The present work is a step towards the practical 380	
demonstration and validation of 3D printing of tablets with high drug loading for the tailored 381	
manufacture of medicines and personalised care and treatment. The work clearly 382	
demonstrates the capability of 3D extrusion based printing to produce acceptable tablets from 383	
approved materials that comply with current USP standards and that if a suitable regulatory 384	
and quality environment can be established that this could be achieved in a distributed 385	
manufacture model. 386	
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                                                        Captions of figures 524	
Figure 1: Photographs of paracetamol immediate release tablets. 525	
Figure 2: In vitro cumulative drug release profile of paracetamol immediate release tablets. 526	
14.7mm length × 7.5 mm width × 5.0 mm height (average, n = 6). 527	
Figure 3: SEM micrograph of paracetamol immediate release 3D tablets (top, cross section, 528	
and bottom). 529	
Figure 4: XRPD patterns of the calculated (top) and reference (measured) paracetamol. 530	
Figure 5: XRPD patterns of paracetamol powder (non-ground and ground Form I) (left), 531	
paracetamol powder (ground Form I), paracetamol formulation, PVP K25, CCS and Brass 532	
(sample holder) (right). 533	
Figure 6: FTIR spectra of paracetamol powder (ground Form I) and paracetamol formulation 534	
(right), PVP K25, CCS (left). 535	
Figure 7: DSC thermograms of pure paracetamol, paracetamol formulation, PVP K25, and 536	
NaCCS. 537	
Figure 8: Schematic diagram represents how application of 3D printing in manufacturing 538	
distribution could change the drug manufacturing process. 539	
 540	
 541	
 542	
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 545	
Figure 1: Photographs of paracetamol immediate release tablets. 546	
 547	
 548	
Figure 2: In vitro cumulative drug release profile of paracetamol immediate release tablets. 14.7mm 549	
length × 7.5 mm width × 5.0 mm height (average, n = 6). 550	
 551	
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 552	
Figure 3: SEM micrograph of paracetamol immediate release 3D tablets (top, cross section, and 553	
bottom). 554	
 555	
Figure 4: XRPD patterns of the calculated (top) and reference (measured) paracetamol. 556	
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 557	
Figure 5: XRPD patterns of paracetamol powder (non-ground and ground Form I) (left), paracetamol 558	
powder (ground Form I), paracetamol formulation, PVP K25, CCS and Brass (sample holder) (right). 559	
 560	
Figure 6: FTIR spectra of paracetamol powder (ground Form I) and paracetamol formulation (left), 561	
PVP K25, CCS (right). 562	
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 563	
Figure 7: DSC thermograms of pure paracetamol, paracetamol formulation, PVP K25, and NaCCS. 564	
	565	
	566	
	567	
	568	
	569	
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	570	
Figure 8: Schematic diagram represents how application of 3D printing in manufacturing distribution 571	
could change the drug manufacturing process. 572	
	573	
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Tables 578	
Table 1: The percentage composition of various ingredients in paracetamol immediate release 579	
formulation feed stock. 580	
Name of Comp.  Function 
Total formulae 
(mg) 
Dry formulae 
(wt. % w/w)  
Wet formulae 
(wt. % w/w)  
Dry tablets* 
(mg ) 
Paracetamol API** 800 80 48.49 254.72 
PVP Binder 112.5 11.25 6.82 35.82 
NaCCS Disintegrant 87.5 8.75 5.30 27.86 
        Water Binder 650 --- 39.40 --- 
 * Calculated from the average of the total paracetamol tablet weight (318.4 mg), ** Active 581	
Pharmaceutical Ingredient  582	
Table 2: Individual paracetamol immediate release 3D printed tablets weight, percentage 583	
deviation, and their average, median, maximum, minimum weight and standard deviation. 584	
Tablet no. Tablet weight 
(mg) 
Deviation % 
1 322.80 1.70 
2 314.20 -1.01 
3 316.90 -0.15 
4 320.90 1.11 
5 320.50 0.98 
6 319.50 0.66 
7 318.50 0.35 
8 310.50 -2.17 
9 315.70 -0.53 
10 321.70 1.36 
11 318.80 0.44 
12 311.80 -1.76 
13 318.80 0.44 
14 322.30 1.55 
15 310.80 -2.08 
16 312.00 -1.70 
17 316.80 -0.19 
18 320.00 0.82 
19 315.00 -0.75 
20 320.30 0.92 
30	
	
Average 317.39 0.00 
Median 318.65 0.40 
Maximum 322.80 1.70 
Minmum 310.50 -2.17 
SD ± 3.80 1.20 
	585	
Table 3: Individual paracetamol immediate release 3D printed tablets breaking force (N), 586	
tensile fracture strength (MPa), and their average, median, maximum, minimum hardness and 587	
standard deviation.  588	
Tablet no. Breaking force (kg) Breaking force (N) Tensile strength (MPa) 
1 8.20 80.40 9.65 
2 7.72 75.70 9.00 
3 8.49 83.30 9.54 
4 7.50 73.60 8.32 
5 8.03 78.80 8.67 
6 7.85 77.00 8.40 
Average 7.97 78.13 8.93 
Median 7.94 77.90 8.84 
Maximum 8.49 83.30 9.65 
Minimum 7.50 73.60 8.32 
SD ± 0.32 3.16 0.52 
	589	
Table 4: Individual immediate release paracetamol 3D printed tablets dimension and their 590	
average, median, maximum, minimum dimension, standard deviation. 591	
 592	
Table 5: Disintegration time of paracetamol 3D printed tablets. 593	
Tab No. Disintegration time (Sec.) 
1 66 
2 60 
3 59 
4 60 
Dimension 
(mm) 
Tablet 
1 
Tablet 
2 
Tablet 
3 
Tablet 
4 
Tablet 
5 
Tablet 
6 
Average 
(mm) 
Median 
(mm) 
Maximum 
(mm) 
Minimum 
(mm) 
SD 
(±) 
Length  14.52 14.51 14.45 14.44 14.59 14.58 14.52 14.52 14.68 14.44 0.0 
Width  7.53 7.59 7.48 7.51 7.53 7.47 7.52 7.52 7.59 7.47 0.04 
Thickness 4.91 4.91 5.03 5.05 5.14 5.18 5.04 5.04 5.18 4.91 0.10 
31	
	
5 57 
6 65 
Average 61 
Median 60 
Maximum 66 
Minimum 57 
SD ± 4 
 594	
 595	
 596	
Supplementary information (Appendix A) 597	
Captions of figures 598	
S. I. Figure 1: Loss on drying data shows total weight of paracetamol immediate release 3D 599	
printed tablets (placed on a hot plate at a fixed temperature 80 °C) as function of time 600	
S. I. Figure 2: Calibration curve of paracetamol in phosphate buffer medium at pH 6.8. 601	
Tables 602	
S. I. Table 1: Loss on drying data shows total weight of paracetamol immediate release 3D 603	
printed tablets (placed on a hot plate at a fixed temperature 80 °C) as function of time. 604	
Time (hrs) 
Tablet total wt. (mg) 
Tablet 1 Tablet 2 Tablet 3 Average wt. 
01:00 395.5 393.1 394.2 394.3 
01:15 377.7 378.4 380.2 378.8 
01:30 370.3 365.2 366.5 367.3 
01:45 358.9 354.1 356.4 356.5 
02:00 348.2 343.9 345.7 345.9 
32	
	
02:15 339.1 335.7 335 336.6 
02:30 332.4 328.8 331 330.7 
02:45 327.1 325 326.8 326.3 
03:00 323.8 323.5 324 323.8 
03:15 322.7 322.4 323.8 322.6 
03:30 322.6 322.3 322.4 322.4 
 605	
